BioNTech SE

Merck and Moderna announced positive topline Phase 3 results for their individualized cancer vaccine intismeran autogene in resected melanoma, beating Keytruda alone on recurrence-free survival, though no specific efficacy numbers have been released yet. The news lifted several biotech names, with BioNTech surging 21.6% on read-across excitement and Illumina rising 15.6% to $223.22 because its NovaSeq X sequencers are required for every individualized neoantigen dose manufactured. Pacific Biosciences gained 5.8% to $1.28, Repligen traded at $181.62 after reporting second-quarter revenue of $204 million with 13% organic growth, and Danaher saw mid-teens bioprocessing order growth in the second quarter. Leerink Partners analyst Daina Graybosch called the market reaction overly optimistic but still raised her 2032 intismeran forecast to $1.4 billion, while Morningstar projects $16.8 billion by 2035.

BioNTech SE has already presented new clinical data from its broad lung cancer pipeline at the 2026 IASLC World Conference on Lung Cancer in Seoul, covering key assets pumitamig, gotistobart and several mRNA-based immunotherapy approaches. The company's first-in-class combination data pairing its PD-(L)1 x VEGF bispecific antibody pumitamig with a B7H3-targeted antibody-drug conjugate underscores BioNTech's push into differentiated, novel-novel immunotherapy regimens in lung cancer. The new WCLC lung cancer data reinforces that pivot but does not, by itself, change the near term reality that BioNTech is unprofitable, dependent on pipeline progress, and exposed to the risk that key late stage trials fail to convert into meaningful non COVID revenue. Among recent developments, the May 30 ROSETTA Lung program update on pumitamig stands out alongside the new pumitamig plus B7H3 ADC data, framing a clearer near term catalyst path in lung cancer around multiple Phase 3 readouts. BioNTech's narrative projects €2.2 billion revenue and €374.5 million earnings by 2029, while the most pessimistic analysts once modeled a 25.6% annual drop to about €1.1 billion by 2029.

Moderna and Merck announced positive phase III results for their personalized mRNA cancer therapy intismeran autogene in high-risk melanoma, sending Moderna shares up 177% and adding more than $44 billion to its market capitalization. The INTerpath-001 study met its primary endpoint of recurrence-free survival and a key secondary goal of distant metastasis-free survival in patients treated with intismeran plus Merck's Keytruda, though no specific numbers were disclosed. The companies said the results represent the first positive phase III readout for an individualized neoantigen therapy and an mRNA-based cancer therapy, and they plan to engage with regulators on potential filings. Merck shares closed about 13% higher, while BioNTech rose 22% as investors saw validation for mRNA oncology platforms. Moderna and Merck are testing intismeran across nine phase II and phase III studies in other cancers including non-small cell lung cancer, bladder cancer, and renal cell carcinoma.

Moderna and Merck announced positive Phase 3 results for an individualized mRNA cancer vaccine, marking the first successful late-stage trial of its kind. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. Elon Musk said mRNA technology could fundamentally change how diseases are treated, making medicine more of a software problem than a biological one. Moderna shares skyrocketed 176.97% to close at $174.38, while Merck closed 12.6% higher at $152.20. BioNTech gained 21.96% and Arcturus Therapeutics closed 25.21% higher as peers rallied on the news.

Biotech stocks reached their highest level since the height of the pandemic after Moderna and Merck announced that a late-stage trial testing their messenger RNA-based cancer therapy met its main goals. Healthcare became the best-performing sector in the S&P 500, with the State Street SPDR S&P Biotech ETF adding more than 4% to reach its highest level since February 2021. The individualized neoantigen therapy intismeran autogene, combined with Merck's Keytruda, improved recurrence-free survival with a statistically significant and clinically meaningful effect in the Phase 3 INTerpath-001 trial. Moderna shares more than doubled, Merck added over 12%, and rival vaccine makers BioNTech and Novavax also gained sharply. Gene editing companies including Prime Medicine, Intellia, CRISPR, Editas Medicine, and Beam Therapeutics were notable gainers, while AI-related biotechs Absci and Recursion Pharmaceuticals rallied after Anthropic selected Twist Bioscience as an independent evaluator.

Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its personalized mRNA cancer therapy developed with Merck sent investors piling into the stock. The vaccine, intismeran, reduced the risk of recurrence and spread of skin cancer when combined with Merck's blockbuster immunotherapy drug Keytruda in a late-stage trial. Leerink Partners analysts now expect about $1.4 billion sales potential for the therapy by 2032, up from their previous projection of up to $1.2 billion. Short sellers faced record one-day losses, with short interest at 13.5% of the free float, according to ORTEX. The Nasdaq biotech index rose 4.4% to a fresh record high, while BioNTech climbed 20% and Novavax rose 6%.

Pfizer and BioNTech have secured European Commission marketing authorisation for their COVID-19 vaccine formulation targeting the XFG variant. The approval covers active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older, and is valid in all 27 European Union Member States plus Iceland, Liechtenstein and Norway. The decision follows a recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use in July 2026, based on guidance from the agency’s Emergency Task Force to update vaccines against the XFG variant. The companies have already begun at-risk manufacturing of the monovalent XFG-adapted vaccine to ensure supply readiness ahead of the respiratory disease season, and have submitted data to other regulatory authorities.

The head and neck squamous cell carcinoma market is projected to grow at a compound annual growth rate of 10.5% during the 2026 to 2036 forecast period, driven by the launch of emerging novel immunotherapies. The market size across the seven major markets—the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan—was valued at USD 850 million in 2025, with the United States accounting for the largest share. Key therapies in development include Amivantamab from Johnson & Johnson, BNT113 from BioNTech, Petosemtamab from Genmab, and Eftilagimod Alfa from Immutep, among others. The total incident cases of head and neck squamous cell carcinoma in the seven major markets were approximately 153,500 in 2025. KEYTRUDA generated the highest revenue among all therapies for the disease in the United States that year.

A new report from DelveInsight reveals that more than 28 companies are actively developing over 30 pipeline drugs for tuberculosis. Key players include Biofabri, Otsuka Pharmaceutical, GlaxoSmithKline, Archivel Farma, BioNTech, CanSino Biologics Inc., Medincell, and others, with promising therapies such as MTBVAC, Quabodepistat, GSK3036656, RUTI, BNT164, and Ad5-105K in various clinical stages. Approximately four-plus drugs are in late-stage development, and notable mechanisms of action include leucyl-tRNA synthetase inhibitors, immunostimulants, and DprE1 protein inhibitors. The report also highlights recent milestones, including the first patient dosed in a Phase IIb trial of alpibectir-ethionamide in March 2026 and the initiation of a new cohort in the IMAGINE trial of MTBVAC in February 2026.

The global vaccine sales market is projected to grow from US$76.40 billion in 2026 to US$141.40 billion by 2036, expanding at a compound annual growth rate of 6.3%. Growth is supported by rising infectious disease prevalence, broader government-funded immunisation programmes in low- and middle-income countries, and sustained investment in mRNA, viral vector, DNA and needle-free vaccine technologies. Platform-based technologies are enabling developers to pursue multiple disease targets, with programmes such as Moderna and Merck's mRNA-4157 illustrating the expanding role of mRNA in oncology. In December 2025, the Coalition for Epidemic Preparedness Innovations committed up to US$54.3 million to support a Phase III trial of Moderna's mRNA-based H5 pandemic influenza vaccine candidate, advancing the first mRNA influenza vaccine into pivotal-stage development. The market remains sensitive to U.S. tariff policies and supply-chain pressures, prompting companies to localise manufacturing and diversify suppliers. Key players include GSK, Pfizer, Sanofi, Moderna, Merck, BioNTech, AstraZeneca and Serum Institute of India, with the report profiling 21 companies in total.

The head and neck squamous cell carcinoma market is projected to grow at a compound annual growth rate of 10.5% during the 2026–2036 forecast period, driven by the launch of emerging novel immunotherapies. The market size across the seven major markets—the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan—was estimated at USD 850 million in 2025, with the United States accounting for the largest share. Key therapies in development include Amivantamab from Johnson & Johnson, BNT113 from BioNTech, CUE-101 from Cue Biopharma, Petosemtamab from Genmab, and Eftilagimod Alfa from Immutep, among others. The total incident cases of head and neck squamous cell carcinoma in the seven major markets were approximately 153,500 in 2025. Growth is further supported by rising cancer incidence, increasing adoption of immunotherapies and targeted therapies, and a robust pipeline of investigational drugs.

The in silico protein design market is projected to grow from $1.87 billion in 2025 to $4.86 billion in 2030, at a compound annual growth rate of 20.9%. Key drivers include advances in computational biology, increased availability of protein structure databases, and expanding use in drug discovery and personalized medicine. Major trends shaping the market are AI-driven protein modeling platforms, cloud-based simulation software, machine learning integration in structure prediction, and computational enzyme engineering. In July 2023, BioNTech SE acquired InstaDeep Ltd. to combine immunotherapy with advanced AI and machine learning for accelerated drug discovery. North America was the largest region in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Arcus Biosciences announced a clinical trial collaboration with Bristol-Myers Squibb to add its investigational kidney cancer drug casdatifan to Bristol-Myers's ongoing Phase 1/2 ROSETTA RCC-208 trial. The trial is evaluating pumitamig, an investigational bispecific antibody jointly developed by BioNTech and Bristol Myers Squibb for advanced renal cell carcinoma. Arcus will supply casdatifan for two new treatment arms added to the existing trial structure, with both companies retaining full development and commercial rights to their respective drugs. Arcus CEO Terry Rosen stated the collaboration is a top priority to potentially deliver an additional effective TKI-free option in the first-line setting.

The global mRNA cancer vaccine market is projected to exceed US$1.20 billion by 2026, according to a new report from ResearchAndMarkets.com. The market is expected to see continued robust growth through 2036, driven by advances in precision oncology, sequencing technologies, and an expanding pipeline of clinical candidates. Key players such as BioNTech, Moderna, Arcturus Therapeutics, and Sana Biotechnology are advancing platform and clinical innovations, while innovations like self-amplifying mRNA constructs and improved lipid nanoparticle delivery systems are enhancing scalability. The report also highlights that production relies on globally sourced inputs like lipid nanoparticles and nucleotides, making supply chains vulnerable to tariffs and disruptions, which could impact costs and development timelines. The analysis covers market segmentation by vaccine type, therapeutic approach, clinical phase, indication, and end-user across regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Legend Biotech and BioNTech are emerging as potential acquisition targets amid a surge in pharmaceutical dealmaking. The sector saw over $65 billion in mergers and acquisitions in the first quarter, the best since 2020, with 16 deals of at least $1 billion each. Legend Biotech’s Carvykti therapy for multiple myeloma generated $597 million in first-quarter sales, up 62% year over year, and partner Johnson & Johnson projects peak annual sales above $5 billion. The company also reported a 100% objective response rate in phase 1 data for its next-generation in vivo CAR-T therapy and has a 99% manufacturing success rate. BioNTech holds 16.8 billion euros in cash and investments, offsetting a large portion of any purchase price, and has more than 25 phase 2 and phase 3 trials, including six late-stage readouts expected this year. Co-founders Uğur Şahin and Özlem Türeci plan to transition out of management by the end of 2026, potentially opening the door to a buyout. Both stocks have fallen more than 13% over the past year, and neither company is profitable.

Cancer treatment is undergoing a major transformation as a new generation of biotechnology companies develops smarter, more targeted therapies. BioNTech, known for its COVID-19 vaccine, has expanded into oncology with mRNA cancer vaccines and personalized immunotherapies. Summit Therapeutics has seen success with ivonescimab, a novel immunotherapy for lung cancer. CG Oncology is working on an oncolytic immunotherapy platform for bladder cancer. NeOnc Technologies is developing targeted oncology therapies for significant unmet medical needs. These four companies represent different facets of a broader movement toward more personalized and innovative cancer care.